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Improving the Odds in the
Evaluation of Chest Pain*
Andrew J. Taylor, PHD
Melbourne, Victoria, Australia
Medicine is a science of uncertainty and an art of probability.
—William Osler (1)
Currently, more than 6 million Americans experience chest
pain suggestive of coronary artery disease (CAD) (2). In
addition to the physical symptoms, chest pain carries a large
emotional burden because of the still unacceptably high rate
of cardiovascular death in the community, and the patient’s
fear that their symptoms may be a harbinger of future heart
attack or even death. The evaluation of chest pain is not
simply limited to diagnosis and treatment; patients also look
to their clinician for reassurance of their future cardiac
health.
For decades, exercise electrocardiography (XECG) has
been the first-line investigation in the evaluation of sus-
pected CAD (3). This is not simply due to its widespread
availability, economy, and diagnostic accuracy. Although
the sensitivity and specificity of XECG for obstructive
CAD are both modest at around 70% (4), a negative XECG
See page 2205
carries an excellent prognosis, with a 5-year survival of 97%
(5). Even if we are uncertain about the absence of CAD
with a negative XECG, we are reassured by the low
probability of future adverse CAD events. Although stress
echocardiography and nuclear cardiology have advanced
both diagnostic accuracy and the capacity to determine the
location and extent of ischemia (6,7), the landscape has been
further changed by coronary computed tomographic an-
giography (cCTA). With multidetector (64 slice and above)
cCTA, the sensitivity for the presence of obstructive CAD
approaches or even exceeds 95% (8,9), and coronary ana-
tomic information previously only available through invasive
angiography is obtained. It is therefore not surprising that a
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In a large, single center retrospective cohort study, Cho et
al. (10) compared the prognostic value of 64-slice cCTA
versus XECG in a group of 2,977 registry patients with
suspected CAD, 95% of whom had angina or angina
equivalent. All patients underwent the 2 tests within 90
days, with a median interval of only 8 days. The primary
endpoint was the rate of major adverse cardiac events
(MACEs), defined as cardiac death, nonfatal myocardial
infarction, unstable angina, and revascularization over a
median follow-up of 3.3 years. In multiple prognostic
models that included clinical risk factors, cCTA provided
improved discrimination for future MACEs over XECG
alone, whereas XECG did not improve discrimination for
future MACEs over cCTA alone. When stratified accord-
ing to a negative or positive XECG, cCTA had added
benefit in predicting MACEs in both strata. However,
although XECG provided added benefit in predicting
MACEs in patients with moderate or severe CAD on
cCTA, it did not provide a benefit in patients with minimal
or no CAD on cCTA.
Although one might hypothesize, as the investigators do,
that due to its combination of high diagnostic accuracy and
improved prognostication, cCTA could become the first-
line test of suspected CAD, it is important to take a deeper
look at the study findings to determine what benefits would
be achieved by this approach. The dominant contributor to
future MACEs in the study was coronary revascularization
(most of which was percutaneous coronary intervention),
which accounted for 80% of all MACEs. Although
coronary revascularization was only included in MACEs if
it occurred 90 days after the index test, the confounding
effect of cCTA driving the study endpoints cannot be
ignored, because 60% of coronary revascularizations were
or lesions deemed to be obstructive at the index cCTA.
lthough percutaneous coronary intervention for stable
AD provides excellent control of angina, it has not been
hown to reduce the rate of future death or myocardial
nfarction (11); therefore, any benefit of a cCTA-first
pproach would be mostly limited to the improved identi-
cation of those in whom intervention might provide a
ymptomatic benefit. The rate of “hard” CAD endpoints,
uch as death, myocardial infarction, or unstable angina, in
atients with a negative XECG was extremely low, with
nly 6 such events in nearly 2,500 patients during the
ollow-up period. There are many other aspects that would
equire clarification before elevating cCTA to the first-line
est for suspected CAD, most notably the competing role of
unctional modalities, such as perfusion imaging and stress
chocardiography versus anatomic imaging, the potential
arm of radiation, and also cost efficacy.
An alternative interpretation of the study findings is that
he current XECG-first algorithm for suspected CAD is
ppropriate, but those with a positive XECG should un-
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November 20/27, 2012:2216–7 CCTA versus XECGdergo cCTA and only proceed to invasive angiography if
cCTA demonstrates moderate or worse CAD. Patients with
a positive XECG but “negative” cCTA (defined by normal
or 40% stenosis) had no significant increase in MACEs
compared with those with negative results in both tests,
which supports the safety of such an approach. Because only
slightly more than one-third of patients who undergo invasive
angiography for suspected CAD have been found to have
obstructive disease (12), cCTA may play a “gatekeeper” role in
preventing unnecessary invasive coronary angiograms. One
would speculate that such an approach, were it proven safe and
effective, could lead to significant cost savings.
An important shortfall in this study is the lack of
information on medical therapies targeted against athero-
sclerosis, such as antiplatelet agents, angiotensin-converting
enzyme inhibitors, and lipid-lowering medications. This is
particularly relevant given the absence of data evaluating the
treatment of patients with nonobstructive disease identified
by cCTA. A patient with a negative XECG would generally
be reassured that they have noncardiac pain and often only
lifestyle measures would be recommended. However, the
management of a patient with noncardiac pain but non-
obstructive CAD on cCTA is more confusing. Although
such patients may be at higher risk of future CAD events
(13), whether this justifies aggressive antiatherosclerotic
therapy is unknown. Also, in addition to the uncertainty
related to its management, a diagnosis of CAD in even mild
form has important legal, occupational, and emotional
implications.
The study by Cho et al. (10) provides valuable informa-
tion relating to the interaction of cCTA findings and
XECG with respect to future prognosis, which should aid
clinicians in selecting the appropriate investigation for the
evaluation of chest pain. Uncertainty remains with respect
to exactly where cCTA sits in the investigational algorithm
of chest pain, and also as to how we might best manage the
growing number of patients with minor CAD identified by
cCTA and noncardiac chest pain. However, the additional
prognostic information obtained by cCTA may now enable
us to provide even greater reassurance to our patients, that
the odds of a healthy cardiac future are good.
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